Skip to main content
NOVT
NASDAQ Manufacturing

Novanta Q3 Revenue Up 23% to $305M; Q4 EPS Guidance Flat at 0-5% Growth

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Scientific Instrument Stocks · Technology
Sentiment info
Neutral
Importance info
7
Price
$146
Mkt Cap
$5.521B
52W Low
$98.27
52W High
$176.375
52W Position info
49% above low
Off High info
17% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

NOVT sits 49% above its 52-week low of $98.27.

Summary

Novanta grew Q3 revenue 23% to $305M and Adjusted EBITDA 38% to $80.3M, but GAAP EPS fell to $0.05 and fourth-quarter EPS guidance implies only 0-5% growth.


Key Events · Earnings and Guidance · NOVT

  • Q3 Revenue Jumps 23% to $305M

    GAAP revenue rose 23.1% to $305.0M from $247.8M, with acquisitions adding 13.3 points and organic growth at 9.9%.

  • GAAP EPS Collapses to $0.05

    GAAP net income fell to $2.0M from $10.7M as $51.2M of non-GAAP adjustments — including $21.4M intangible amortization and $19.2M acquisition costs — drove Adjusted Diluted EPS up 21% to $1.05.

  • Q4 Guidance Shows Sharp Deceleration

    Fourth-quarter Adjusted Diluted EPS is guided to $0.91-$0.96, or 0% to 5% growth, on revenue of $306-312M; full-year Adjusted Diluted EPS is guided to $3.66-$3.71.

  • Leverage Rises After Riverpoint Deal

    Net debt stands at $689.4M versus net cash of $121.3M at December 31, 2025, after $1.2B paid for Riverpoint Medical and $626M drawn on the senior credit facilities.


Analysis · NOVT · Manufacturing

Revenue and adjusted profit beat the company's own expectations, but the headline numbers hide a wide GAAP-to-adjusted gap: $51.2M of adjustments (mostly acquisition amortization and deal costs) turned $2.0M of GAAP net income into $45.0M adjusted. The bigger issue for holders is the fourth-quarter guide, which calls for Adjusted Diluted EPS of $0.91-$0.96, or 0% to 5% growth — a sharp deceleration from the 21% just reported, and the reason this quarter's beat may not carry the stock. Balance sheet leverage is now real: net debt of $689.4M after the $1.2B Riverpoint deal, versus net cash of $121.3M at the start of the year.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NOVT was trading at $146.00 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $98.27 to $176.38. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NOVT - Latest Insights

NOVT
Nov 09, 2026, 5:00 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $144.00
Real-time Price: $141.00 info
Change: -$3.00 (-2%) info
Market Cap: $5.521B info
NOVT
Nov 09, 2026, 4:45 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $146.00
Real-time Price: $141.00 info
Change: -$5.00 (-3%) info
Market Cap: $5.521B info
NOVT
Oct 02, 2026, 4:30 PM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $149.27
Real-time Price: $141.00 info
Change: -$8.27 (-6%) info
Market Cap: $5.521B info
NOVT
Aug 05, 2026, 5:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $158.00
Real-time Price: $141.00 info
Change: -$17.00 (-11%) info
Market Cap: $5.521B info
NOVT
Aug 05, 2026, 4:45 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $153.12
Real-time Price: $141.00 info
Change: -$12.12 (-8%) info
Market Cap: $5.521B info